Patents Assigned to Diaclone
  • Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers
    Patent number: 8722043
    Abstract: The present invention relates to the use of anti-human neuropilin-2 antibodies, or of ligands of human neuropilin-2 derived from these antibodies, for obtaining a medicament intended to increase p53 expression and to induce tumor cell apoptosis in the context of an anticancer treatment.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: May 13, 2014
    Assignees: Diaclone, EFS Bourgogne Franche Comte, Universite de Franche Comte
    Inventors: Christophe Borg, John Wijdenes, Camille Grandclement
  • Humanized B-B10
    Patent number: 5886152
    Abstract: A humanized antibody is provided, which is obtained by transplantation of the complementarity determining region of a mouse monoclonal antibody B-B10 specific to a human IL-2 receptor into a human antibody. The antibody has a very low antigenicity, and therefore, it is useful for treatment of carcinoma expressing IL-2 receptor.
    Type: Grant
    Filed: May 10, 1994
    Date of Patent: March 23, 1999
    Assignees: Sumitomo Pharmaceuticals Company, Limited, Biotest Pharma GbmH, Diaclone
    Inventors: Tomoyuki Nakatani, Hideyuki Gomi, John Wijdenes, Hiroshi Noguchi